Psilocybin Therapy for depression / HighBrid Lab - LARVOL DELTA

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Halucenex Life Sciences Inc. | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Oct 2023

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Halucenex Life Sciences Inc. | Trial completion date: Mar 2023 ➔ Sep 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Halucenex Life Sciences Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Halucenex Life Sciences Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Halucenex Life Sciences Inc. | Trial completion date: Nov 2022 ➔ Mar 2023 | Initiation date: Apr 2022 ➔ Sep 2022 | Trial primary completion date: May 2022 ➔ Dec 2022

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Red Light Holland Expected Merger Partner Creso Pharma Completes Acquisition of Halucenex Life Sciences Inc (Streetinsider.com) - "Red Light Holland Corp....is pleased to announce that Creso Pharma Ltd. ('Creso Pharma') has completed its previously announced acquisition of Halucenex Life Sciences Inc....Halucenex is expected to begin phase II clinical trials to demonstrate the efficacy of Psilocybin therapy in the treatment of treatment-resistant depression in Canadian veterans and everyday individuals living with debilitating conditions. In May, Halucenex secured additional GMP grade synthetic psilocybin, taking total secured inventory to 22.3 grams...Halucenex will now progress the USP 62 test, which will highlight the shelf life of its psilocybin samples, as well as provide additional validation."

M&A • CNS Disorders • Depression • Major Depressive Disorder